New drugs, such as sodium-glucose co-transporter inhibitors and glucagon-like peptide-1 receptor agonists that do not cause hypoglycemia and are associated with cardiovascular benefits, are available for the management of T2D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.